SLC5A2 and diabetes mellitus: According to the consensus report of the American Diabetes Association and the European Association of the Study of Diabetes, SGLT2 inhibitors are considered the first-choice glucose-lowering agent for type 2 DM patients at a high risk for cardiovascular disease and heart failure.